1Cortes-Hernandez J,Ordi-Ros J,Labrador M,et al.Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone[J].Lupus,2003,2 (4):287-296.
2Mok CC.Prognostic factors in lupus nephritis[J].Lupus,2005,14(1):39-44.
4Mok CC,Lai KN.Mycophenolate mofetil in lupus glomerulonephritis[J].Am J Kidney Dis,2002,40(3):447-457.
5Illei GG,Austin HA,Crane M,et al.Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis[J].Ann Intern Med,2001,35 (4):248-257.
6Chiu S J,Ou LS,Tsai TL,et al.Sequential evaluation of clinical and laboratory changes amongst children suffering from lupus nephritis during intermittent intravenous cyclophosphamide therapy[J].Clin Rheumatol,2005,10:1-5.
8Arcasoy MO,Chao NJ.T-cell-mediated pure red-cell aplasia in systemic lupus erythematosus:response to cyclosporin A and mycophenolate mofetil[J].Am J Hematol,2005,78 (2):161-163.
10Sherer Y,Shoenfeld Y.Intravenous immunoglobulin for immunomodulation of systemic lupus erythematosus[J].Autoimmun Rev,2006,5 (2):153-155.
二级参考文献3
1Mayer AD, Dmitrewski J, Squitflet JP, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection:a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation, 1997,64: 436-443.
2Shaw KT, Ho AM, Raghavan A, et al.Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells. Proc Natl Acad Sci USA, 1995, 92:11205-11209.
